Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering
studies to understand the molecular and cellular wiring of response and resistance. Our …

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …

Metastatic melanoma is a complex and deadly disease. Due to its complexity, the
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …

Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC),
only a subset of patients will respond due to a heterogenous tumor microenvironment …

Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …

Over the past decade, Next-Generation Sequencing (NGS) has advanced our
understanding, diagnosis, and management of several areas within dermatology. NGS has …

Methods There were 12 ALK rearrangement-positive tumor specimens from patients with
non-small cell lung cancer (NSCLC) previously detected via fluorescence in situ …

Objectives To validate a large next-generation sequencing (NGS) panel for comprehensive
genomic profiling and improve patient access to more effective precision oncology treatment …

Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid
biopsy testing is a complementary approach to tissue testing, particularly when tissue is not …

Introduction: Next-generation sequencing (NGS) is currently widely used for biomarker
studies and molecular profiling to identify concurrent alterations that can lead to the better …